MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • CytRx Corp. (CYTR) Potential Emphasized In Seeking Alpha Article 0 comments
    Jan 2, 2014 3:20 PM | about stocks: CYTR

    CytRx, a biopharm research and development company specializing in cancer treatment, was recently featured in an article by Seeking Alpha contributor Equity Options Guru who highlights the potential of the company's pipeline of oncology treatment candidates.

    Aldoxorubicin is the company's improved version of doxorubicin, a commonly used chemotherapeutic agent saddled with significant risk of adverse events stemming from high levels of toxicity.

    To read the full article visit: seekingalpha.com/article/1922201

    CytRx in early December reported positive phase 2b trial of aldoxorubicin for first-line metastatic, locally advanced, or unresectable soft tissue sarcomas. In the study, both an investigator assessment and a central lab review agreed that aldoxorubicin was superior to doxorubicin. Furthermore, aldoxorubicin was found to be safe and well-tolerated with no treatment-related deaths.

    As the article notes, shares of CytRx have soared nearly 200 percent over the past year along the course of development of aldoxorubicin. The author suggests that shares will head even higher in 2014 based on several upcoming anticipated events:

    •Phase 2 Trial Initiation for Kaposi's Sarcoma - Expected in late 2013/early 2014

    •Phase 3 Trial Initiation for 2nd-Line Soft Tissue Sarcoma - Expected during 1st quarter 2014

    •Preliminary Phase 2 GBM (glioblastoma multiforme) results - Expected during 3rd quarter 2014

    •Overall survival data from Phase 2b 1st-Line Soft Tissue Sarcoma Trial - Expected during 3rd quarter 2014

    Equity Options Guru also outlines CytRx's financial position and possible future partnerships to strengthen product advancement.

    In conclusion, Equity Options Guru writes, "CytRx Corporation certainly seems well on its way for future growth. The Phase 2b STS results were extremely encouraging not only for that indication but for the applicability of aldoxorubicin to other indications. If the company continues to execute over the next couple of years like it has over the past couple, there is no telling how high the share price could go."

    For more information, visit cytrx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.